Back to search results

Observational Study of Responses to Treatments in Advanced CNS Tumors

This study is looking at a new technology called SmartMatch, which helps find the best medicines for central nervous system (CNS) tumors by testing how small pieces of tumor tissue react to different drugs. Researchers want to see if SmartMatch can complete this analysis and provide a report within 21 days after surgery. This study is for people aged 15 and older who have recurrent CNS tumors, including specific types of gliomas, and are already scheduled for a brain tumor biopsy or surgery at the NIH. The goal is to better understand these tumors to find improved treatments in the future. The study involves collecting a fresh tumor sample during your planned surgery.

Study design
This is an interventional study with a planned enrollment of 80 participants. The phase of the study is not specified.
What's involved
You would provide a fresh tumor sample for the study, which would be collected during your already planned biopsy or surgery at the NIH.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to determine if SmartMatch results can be generated within 21 days from tumor tissue acquisition.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07374692

Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors

Recruiting
NAAges 15+Interventional
National Cancer Institute (NCI)
~80 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:Tumor sample collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To determine the proportion of participants with advanced CNS tumors for whom SmartMatch drug screen analysis results are generated within 21 days from the time of tumor tissue acquisition
Measured over 21 days from the time of tumor tissue acquisition

Conditions

Recurrent CNS Tumors
Brain Cancer
Gliomas
IDH-wildtype Gliomas
IDH-mutant Gliomas
Rare CNS Tumor

Explore related trials

Central Nervous System NeoplasmGlioma

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Jing Wu, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Christine T McGowan
[email protected]
(240) 858-7330
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have advanced CNS tumors confirmed by a documented pathology report, including:
recurrent isocitrate dehydrogenase (IDH)-wild-type high-grade glioma
recurrent IDH-mutant gliomas
other recurrent CNS tumors
Participants must have been scheduled for a brain tumor biopsy or resection. Note: Scheduled brain tumor biopsy or resection must be at least 6 months after any previous radiation therapy, if applicable. All procedures are planned to take place at NIH.
Age \>= 15 years.
Ability of participant, parent/guardian, or Legally Authorized Representative (LAR) to understand and sign a written informed consent document.

What this trial measures

  • To determine the proportion of participants with advanced CNS tumors for whom SmartMatch drug screen analysis results are generated within 21 days from the time of tumor tissue acquisition21 days from the time of tumor tissue acquisition

    Point estimates and 95% exact confidence intervals will be calculated using the Clopper-Pearson method